- Home
- IPXX vs ZNTL Comparison
IPXX vs ZNTL Comparison
Compare IPXX & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPXX
- ZNTL
- Stock Information
- Founded
- IPXX 2023
- ZNTL 2014
- Country
- IPXX United States
- ZNTL United States
- Employees
- IPXX N/A
- ZNTL N/A
- Industry
- IPXX Blank Checks
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- IPXX Finance
- ZNTL Health Care
- Exchange
- IPXX Nasdaq
- ZNTL Nasdaq
- Market Cap
- IPXX N/A
- ZNTL 238.2M
- IPO Year
- IPXX 2023
- ZNTL 2020
- Fundamental
- Price
- IPXX $10.77
- ZNTL $3.00
- Analyst Decision
- IPXX
- ZNTL Buy
- Analyst Count
- IPXX 0
- ZNTL 7
- Target Price
- IPXX N/A
- ZNTL $10.86
- AVG Volume (30 Days)
- IPXX 83.3K
- ZNTL 1.4M
- Earning Date
- IPXX 01-01-0001
- ZNTL 11-04-2024
- Dividend Yield
- IPXX N/A
- ZNTL N/A
- EPS Growth
- IPXX N/A
- ZNTL N/A
- EPS
- IPXX 0.40
- ZNTL N/A
- Revenue
- IPXX N/A
- ZNTL $40,560,000.00
- Revenue This Year
- IPXX N/A
- ZNTL N/A
- Revenue Next Year
- IPXX N/A
- ZNTL N/A
- P/E Ratio
- IPXX $27.09
- ZNTL N/A
- Revenue Growth
- IPXX N/A
- ZNTL N/A
- 52 Week Low
- IPXX $10.21
- ZNTL $2.83
- 52 Week High
- IPXX $11.00
- ZNTL $18.32
- Technical
- Relative Strength Index (RSI)
- IPXX 60.43
- ZNTL 39.05
- Support Level
- IPXX $10.76
- ZNTL $2.89
- Resistance Level
- IPXX $10.77
- ZNTL $3.06
- Average True Range (ATR)
- IPXX 0.01
- ZNTL 0.17
- MACD
- IPXX -0.00
- ZNTL -0.04
- Stochastic Oscillator
- IPXX 50.00
- ZNTL 12.36
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.